Do we detect a new spectrum of biologically benign melanomas in the dermoscopy era?

Expert Review of Dermatology

Volumn 1, Issue 3, 2006, Pages 361-367

  Argenziano, Giuseppe ^a   Zalaudek, Iris ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

dermoscopy; digital dermoscopy; epidemic; follow up; incidence; melanoma

Indexed keywords

EID: 34250753991     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.1.3.361     Document Type: Article

References (40)

1. Ackerman AB. No one should die of malignant melanoma. J. Am. Acad. Dermatol. 12, 115–116 (1985).
2. Zalaudek I, Ferrara G, Argenziano G, Ruocco V, Soyer HP. A practical guide on the diagnosis and treatment of cutaneous melanoma. Skin Med. 2, 20–31 (2003).
3. Ackerman AB. Disagreements with the current classification of malignant melanomas. Am. J. Surg. Pathol. 6, 733–743 (1982).
4. Ackerman AB, David KM. A unifying concept of malignant melanoma: biologic aspects. Hum. Pathol. 17, 438–440 (1986).
5. Swerlick RA, Chen S. The melanoma epidemic: more apparent than real? Mayo Clin. Proc. 72, 559–564 (1997).
6. Florez A, Cruces M. Melanoma epidemic: true or false? Int. J. Dermatol. 43, 405–407 (2004).
7. Beddingfield FC III. The melanoma epidemic: res ipsa loquitur. Oncologist 8, 459–465 (2003).
8. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. Br. Med. J. 331, 481 (2005).
9. Burton RC, Armstrong BK. Recent incidence trends imply a nonmetastasizing form of invasive melanoma. Melanoma Res. 4, 107–113 (1994).
10. Hiatt RA, Fireman B. The possible effect of increased surveillance on the incidence of malignant melanoma. Prev. Med. 15, 652–660 (1986).
11. Burton RC, Coates MS, Hersey P et al. An analysis of a melanoma epidemic. Int. J. Cancer 55, 765–770 (1993).
12. Swerlick RA, Chen S. The melanoma epidemic. Is increased surveillance the solution or the problem? Arch. Dermatol. 132, 881–884 (1996).
13. Carlson JA, Slominski A, Linette GP et al. Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging. Am. J. Clin. Pathol. 120 (Suppl.), S101 –S127 (2003).
14. Argenziano G, Soyer HP. Dermoscopy of pigmented skin lesions – a valuable tool for early diagnosis of melanoma. Lancet Oncol. 2, 443–449 (2001).
15. Soyer HP, Argenziano G, Talamini R, Chimenti S. Is dermoscopy useful for the diagnosis of melanoma? Arch. Dermatol. 137, 1361–1363 (2001).
16. Bafounta ML, Beauchet A, Aegerter P, Saiag P. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch. Dermatol. 137, 1343–1350 (2001).
17. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 3, 159–165 (2002).
18. Binder M, Schwarz M, Winkler A et al. Epiluminescence microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch. Dermatol. 131, 286–291 (1995).
19. Argenziano G, Soyer HP, Chimenti S et al. Dermocopy of pigmented skin lesions: results of a consensus meeting via the Internet. J. Am. Acad. Dermatol. 48, 679–693 (2003).
20. Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications oberserved in early melanoma, atypical nevi, and common nevi. J. Am. Acad. Dermatol. 43, 467–746 (2000).
21. Menzies SW, Gutenev A, Avramidis M, Batrac A, McCarthy WH. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch. Dermatol. 137, 1583–1589 (2001).
22. Skvara H, Teban L, Fiebiger M, Binder M, Kittler H. Limitations of dermoscopy in the recognition of melanoma. Arch. Dermatol. 141, 155–160 (2005).
23. Kittler H, Binder M. Follow-up of melanocytic skin lesions with digital dermoscopy: risks and benefits. Arch. Dermatol. 138, 1379 (2002).
24. Kittler H, Binder M. Risks and benefits of sequential imaging of melanocytic skin lesions in patients with multiple atypical nevi. Arch. Dermatol. 137, 1590–1595 (2001).
25. Banky JP, Kelly JW, English DR, Yeatman JM, Dowling JP. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch. Dermatol. 141, 998–1006 (2005).
26. Schiffner R, Schiffner-Rohe J, Landthaler M, Stolz W. Long-term dermoscopic follow-up of melanocytic naevi: clinical outcome and patient compliance. Br. J. Dermatol. 149, 79–86 (2003).
27. Malvehy J, Puig S.Follow-up of melanocytic skin lesions with digital total-body photography and digital dermoscopy: a two-step method. Clin. Dermatol. 20, 297–304 (2002).
28. Ferrara G, Zalaudek I, Di Stefani A, Soyer HP, Argenziano G. Do we detect a new spectrum of biologically “benign” melanomas in the dermoscopy era? Melanoma Res. 14, 567–568 (2004).
29. Carli P, Massi D, De Giorgi V, Mannone F, Giannotti B. A 10-year-old in situ melanoma? Arch. Dermatol. 138, 980–981 (2002).
30. Daniotti M, Oggionni M, Ranzani T et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23, 5968–5977 (2004).
31. Balazs M, Adam Z, Treszl A, Begany A, Hunyadi J, Adany R. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 46, 222–232 (2001).
32. Casorzo L, Luzzi C, Nardacchione A, Picciotto F, Pisacane A, Risio M. Fluorescence in situ hybridization (FISH) evaluation of chromosomes 6, 7, 9 and 10 throughout human melanocytic tumorigenesis. Melanoma Res. 15, 155–160 (2005).
33. Treszl A, Ladanyi A, Rakosy Z, Buczko Z, Adany R, Balazs M. Molecular cytogenetic characterization of a novel cell line established from a superficial spreading melanoma. Front. Biosci. 11, 1844–1853 (2006).
34. Pellacani G, Cesinaro AM, Longo C, Grana C, Seidenari S. Microscopic in vivo description of cellular architecture of dermoscopic pigment network in nevi and melanomas. Arch. Dermatol. 141, 147–154 (2005).
35. Carlson JA. Tumor doubling time of cutaneous melanoma and its metastasis. Am. J. Dermatopathol. 25 (4), 291–299 (2003).
36. Shaw H, Thompson J, McCarthy W. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 82 (9), 1799–800 (1998).
37. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 79 (12), 2361–2370 (1997).
38. Gamel JW, George SL, Edwards MJ, Seigler HF. The long-term clinical course of patients with cutaneous melanoma. Cancer 95 (6), 1286–1293 (2002).
39. Harman KE, Fuller LC, Salisbury JR, Higgins EM, du Vivier AW. Trends in the presentation of cutaneous malignant melanoma over three decades at King’s College Hospital, London. Clin. Exp. Dermatol. 29 (5), 563–566 (2004).
40. Guitart J, Lowe L, Piepkorn M et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch. Dermatol. 138 (5), 603–608 (2002).